Metformin boosts the sensitivity of hepatocellular carcinoma to sorafenib via reshaping the tumor microenvironment metabolism

被引：0
|
作者：
Gao, Juan [1 ,2 ]
机构：
[1] Karolinska Inst, Lab Med, BCM, Stockholm, Sweden
[2] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-532
引用
收藏
页码：S435 / S435
页数：1
相关论文
共 50 条
  • [41] Current perspectives on the tumor microenvironment in hepatocellular carcinoma
    Cositha Santhakumar
    Edward J. Gane
    Ken Liu
    Geoffrey W. McCaughan
    Hepatology International, 2020, 14 : 947 - 957
  • [42] PTEN Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib
    Ruan, Zhi-Ping
    Xu, Rui
    Lv, Yi
    Tian, Tao
    Wang, Wen-Juan
    Guo, Hui
    Nan, Ke-Jun
    ONCOLOGY RESEARCH, 2012, 20 (2-3) : 113 - 121
  • [43] Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib
    Bi, Qiu-Chen
    Deng, Zhi-Qiang
    Lv, Yang-Feng
    Liu, Yue
    Xie, Chuan-Sheng
    He, Yuan-qiao
    Tang, Qun
    BIOCHEMICAL PHARMACOLOGY, 2023, 213
  • [44] 3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness
    Gan, Guifang
    Shi, Zhaopeng
    Liu, Dan
    Zhang, Shaoyi
    Zhu, Hui
    Wang, Yugang
    Mi, Jun
    CELL DEATH DISCOVERY, 2021, 7 (01)
  • [45] 3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness
    Guifang Gan
    Zhaopeng Shi
    Dan Liu
    Shaoyi Zhang
    Hui Zhu
    Yugang Wang
    Jun Mi
    Cell Death Discovery, 7
  • [46] Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma
    Qi, Xiangjun
    Guo, Jiayun
    Chen, Guoming
    Fang, Caishan
    Hu, Leihao
    Li, Jing
    Zhang, Chi
    JOURNAL OF IMMUNOLOGY RESEARCH, 2022, 2022
  • [47] Tumor lysis syndrome after treatment with sorafenib for hepatocellular carcinoma
    Kudo, Chieko
    Miura, Masahito
    Gamoh, Makio
    Niitani, Tomohito
    Tamagawa, Hiroki
    Takahashi, Kiichi
    Ichikawa, Sonoko
    Sugiyama, Katsuo
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2015, 4 (03): : 147 - 150
  • [48] Tumor lysis syndrome after treatment with sorafenib for hepatocellular carcinoma
    Chieko Kudo
    Masahito Miura
    Makio Gamoh
    Tomohito Niitani
    Hiroki Tamagawa
    Kiichi Takahashi
    Sonoko Ichikawa
    Katsuo Sugiyama
    International Cancer Conference Journal, 2015, 4 (3) : 147 - 150
  • [49] Prognostic significance of VEGF and HIF 1? in hepatocellular carcinoma patients receiving sorafenib versus metformin sorafenib combination
    Shereen, El Shorbagy
    Rasha, Haggag
    Fouad, Abutaleb
    Labib, Hany A.
    Huda, Ebian
    Ola, Harb
    Mona, Mohammed
    Hanaa, Rashied
    Khaled, Elbana
    Sameh, Saber
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Prognostic and predictive significance of the tumor microenvironment in hepatocellular carcinoma
    Liu, Jibing
    Kuang, Shuwen
    Zheng, Yiling
    Liu, Mei
    Wang, Liming
    CANCER BIOMARKERS, 2021, 32 (01) : 99 - 110
12345